Skip to main content

and
  1. Article

    Open Access

    Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

    Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee in Nature Communications (2021)

  2. Article

    Open Access

    PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

    Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently exp...

    Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee in Nature Communications (2019)